Jeffrey S. Jay

Jeffrey S. Jay

Senior Associate
New York

Email jeffrey.jay@​

Phone +1 212 918 3633

Fax +1 212 918 3100

Practice groupCorporate & Finance

Jeff Jay represents life sciences companies on a variety of corporate, transactional, and commercial matters.

As a member of the firm's Life Sciences and Health Care industry sector team, Jeff provides corporate, transactional, and commercial advice to pre-commercial stage biotechnology companies and commercial-stage pharmaceutical companies. A substantial portion of Jeff's practice involves negotiating complex licensing and collaboration arrangements and other strategic alliances. He also frequently handles other transactional matters for life sciences companies, including mergers and acquisitions. In addition, Jeff drafts and negotiates life sciences-specific operational agreements, such as consulting agreements, material transfer agreements, and services agreements.

Jeff regularly leverages his prior experience as an intellectual property litigator in the pharmaceutical and chemical arts in his practice.

Jeff has been interested in life sciences and health care since majoring in Medicine, Health, and Society at Vanderbilt University. While at Vanderbilt, Jeff worked as a research assistant for Vanderbilt University Medical Center's Center for Patient and Professional Advocacy and co-authored a publication that was awarded the ABIM Foundation's John A. Benson Jr., MD Professionalism Article Prize.

Education and admissions


J.D., Vanderbilt Law School, 2014

B.A., Vanderbilt University, 2011


New York State Bar Association

Bar admissions and qualifications

New York

Representative experience

Advised Novartis in connection with its collaboration with, and option to acquire, IFM Due, Inc.

Advised Gilead in connection with its licenses and collaborations with Agenus Inc., Hookipa Biotech AG, Tango Therapeutics, Inc., and Xencor, Inc.

Advised Celgene in connection with its acquisition of Juno Therapeutics, Inc.

Advised Novartis in connection with its acquisitions of AveXis, Inc., Encore Vision, Inc., and IFM Tre, Inc.

Advised Celgene in connection with the restructuring of its collaboration with Jounce Therapeutics, Inc.

Advised Novartis in connection with its collaboration with Cellular Biomedicine Group, Inc.

Advised Jazz Pharmaceuticals in connection with its acquisition of Cavion, Inc.

Advised Pharmaceutics International, Inc. in connection with the sale of its generics business to Strides Pharma.

Advised an international pharmaceutical company in connection with its acquisition of a priority review voucher.

Regularly advises biotechnology companies in connection with research agreements, services agreements, and other operational agreements.

Loading data